Instead of the usual “ban everything and stick your head in the sand” approach federal agencies so love, the DEA has decided to place their focus on gathering scientific information about five psychedelic tryptamines after pulling back a proposal to ban them. The least they could do, really. However, there is a definite need for oversight and follow-through in order for their new approach to be properly considered and made effective.
What We Know
The Drug Enforcement Administration recently rethought its decision to hold a hearing regarding a scheduling proposal for 5 psychedelic substances. This proposal would have seriously hindered research on their medicinal potential. Thankfully, they have decided against the hearing, opting to task the U.S. Department of Health and Human Services (HHS) with conducting an updated scientific study of the tryptamines in question.
The substances – 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT – were first suggested for scheduling by the DEA in January, a proposal that received a lot of criticism. During a time for public comment, there were close to 600 responses, the majority of which opposed the rule change and asked for a hearing.
Thankfully, the DEA listened to the opinions of the public for once and finally opted against holding a hearing on August 22, despite its own administrative court concurring that a hearing was required before the prohibition could be put into effect. In its most recent notice, the DEA just stated that after giving the scheduling proposal’s circumstances more thought, it had chosen to file a request for HHS review. The agency added that, if necessary, it might issue a new proposed regulation in the future pertaining to these drugs.
The proceedings were initiated by an order issued by Administrative Law Judge Teresa Wallbaum of the DEA in February. The order outlined a schedule for pre-hearing testimony from the agency and interested parties, as well as a date for a pre-hearing conference in May. This is at least a temporary triumph for researchers who contend that categorizing tryptamines as Schedule I, as intended, would substantially impede studies into their medicinal potential.
The Science Of It
It is unclear how long HHS will need to conduct a fresh scientific analysis of the chemicals, and it is also uncertain whether the agency will propose that they remain unscheduled or be added to a less stringent schedule. However, the cancellation of the hearing means that, at the very least, researchers will have more time to conduct independent studies on psychedelics without being constrained by a Schedule I categorization.
According to Matt Zorn, an attorney who represents a client with a research interest in tryptamines, “the decision to get an updated evaluation will allow important research and development to continue that could lead to lifesaving medicines and a better understanding of this drug class.” Zorn is pleased that the Administrator and DEA took a close look at the science and data before it – as are we.
The Office of Administrative Law Judges is especially responsible for making decisions in instances involving DEA enforcement and regulations. The agency’s proposed prohibition was opposed by parties who hoped the judge would ultimately suggest a reduced timetable for the five compounds or no schedule at all. They no longer have to rely, at least temporarily, on the judge’s decision, thanks to the DEA’s most recent action.
According to the DEA, when proposing the scheduling of the five tryptamines, it considered its own eight-factor evaluations as well as previous research and recommendations from the U.S. Department of Health and Human Services (HHS), which determined that the drugs are misused for their hallucinogenic effects.
The usage of two of the tryptamines has been linked to hospitalizations, according to the DEA’s statement in the notice. However, it was only able to mention one death in which 5-MeO-AMT – together with alcohol and an antidepressant – was discovered in the person’s system. “It is unclear what role 5-MeO-AMT played in the death,” the DEA acknowledged.
This seems more in line with federal thinking – having a predetermined idea and using the smallest bit of slightly plausible information to back it up.
The agency’s justification for the proposed ban was contested in hearing request letters that Marijuana Moment was able to obtain earlier this year on the grounds that it was not only unnecessary given the scant evidence of abuse potential – duh – but that it would also obstruct the research and development of medications that could help treat severe mental illnesses.
It is of the utmost importance that any and all research is conducted in a methodical and comprehensive way with full oversight, as well as follow through on findings, in order for this hold on the ban to have the desired – and necessary – effect.
In Other News
Separately, the DEA is being sued once more for its refusal to permit a physician to administer psilocybin therapy to terminally ill patients in accordance with federal and state “Right to Try” (RTT) laws, which aim to increase access to Schedule I investigational drugs that aren’t yet approved for use in the general population.
Bipartisan lawmakers went above and beyond to provide more congressional clarification by submitting companion measures in the House and Senate last week. Their goal was to restate that the scope of Right to Try policy should encompass psychedelics, and these actions are also putting more political pressure on the FDA.
Enjoyed that first hit? Come chill with us every week at the Friday Sesh for a freshly packed bowl of the week’s best cannabis news!
